AstraZeneca Announces FDA Approval For Ultomiris - Quick Facts

(RTTNews) - AstraZeneca (AZN.L, AZN) said Ultomiris has been approved in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The FDA approva https://www.nasdaq.com/articles/astrazeneca-announces-fda-approval-for-ultomiris-quick-facts